omniture
logo
Search
BIOSYNGEN PTE. LTD.
Media Room

Photo News

rss
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

2024-09-20 20:30 1446
Biosyngen Presents Pioneering

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

2024-09-19 20:30 1083
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

2024-09-18 18:18 1413
Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

2024-08-01 16:01 2201
Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

2024-07-16 19:29 2122
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

2024-02-01 17:41 2349
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

2023-10-26 18:18 2611
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

2023-09-18 17:53 2202
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

2023-09-11 14:53 1466
Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

2023-07-12 10:32 3224
Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

2023-06-29 17:14 3507
Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

2023-06-06 12:58 2735
Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

2023-04-18 19:03 3471
Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

2023-04-11 18:09 2512
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

2023-03-29 22:53 3120
Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

2023-02-17 23:13 7815
IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

2022-12-15 13:08 4103
Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A Boost

2022-09-28 17:34 4676
Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited Biosyngen

Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited Biosyngen

2022-05-28 09:00 7078
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City

French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City

2022-01-15 08:00 5384
Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China

Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China

2021-12-29 10:00 4853
12